Current Problems in Cancer
Volume 33, Issue 6 , Pages 333-360 , November 2009

Neuroblastoma

  • Natia Esiashvili, MD

      Affiliations

    • Department of Radiation Oncology, Emory University School of Medicine and Emory Winship Cancer Institute Atlanta, Georgia
    • ,
  • Cynthia Anderson, MD

      Affiliations

    • Department of Radiation Oncology, Emory University School of Medicine and Emory Winship Cancer Institute Atlanta, Georgia
    • ,
  • Howard M. Katzenstein, MD

      Affiliations

    • Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia

References 

  1. Gurney JG, Davis S, Severson RK, Fang JY, Ross JA, Robison LL. Trends in cancer incidence among children in the US. Cancer. 1996;78:532–541
  2. Brodeur GM, Castleberry RP. Neuroblastoma. In:  Pizzo PA,  Poplack DG editor. Principles and practice of pediatrics. Philadelphia, PA: Lippincot-Raven; 1997;p. 761–797
  3. Esiashvili N, Goodman M, Ward K, Marcus RB, Johnstone PA. Neuroblastoma in adults: incidence and survival analysis based on SEER data. Pediatr Blood Cancer. 2007;49:41–46
  4. Gaspar N, Hartmann O, Munzer C, Bergeron C, Millot F, Cousin-Lafay L, et al. Neuroblastoma in adolescents. Cancer. 2003;98:349–355
  5. al-Shammri S, Guberman A, Hsu E. Neuroblastoma and fetal exposure to phenytoin in a child without dysmorphic features. Can J Neurol Sci. 1992;19:243–245
  6. Koren G, Demitrakoudis D, Weksberg R, Rieder M, Shear NH, Sonely M, et al. Neuroblastoma after prenatal exposure to phenytoin: cause and effect?. Teratology. 1989;40:157–162
  7. Olshan AF, Smith J, Cook MN, Grufferman S, Pollock BH, Stram DO, et al. Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. Am J Epidemiol. 1999;150:930–938
  8. De Roos AJ, Olshan AF, Teschke K, Poole C, Savitz DA, Blatt J, et al. Parental occupational exposures to chemicals and incidence of neuroblastoma in offspring. Am J Epidemiol. 2001;154:106–114
  9. Ho TC, Estroff JA, Kozakewich H, Shamberger RC, Lillehei CW, Grier HE, et al. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics. 1993;92:358–364
  10. Jennings RW, LaQuaglia MP, Leong K, Hendren WH, Adzick NS. Fetal neuroblastoma: prenatal diagnosis and natural history. J Pediatr Surg. 1993;28:1168–1174
  11. Hirata T, Tatara H, Zaizen Y, Suita S, Matsuzaki A, Ueda K. Role of ultrasound in managing neuroblastoma detected by mass screening: a proposed ultrasonographic grading for children with neuroblastoma. J Clin Ultrasound. 1995;23:305–313
  12. Holgersen LO, Subramanian S, Kirpekar M, Mootabar H, Marcus JR. Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg. 1996;31:153–155
  13. Murphy SB, Cohn SL, Craft AW, Woods WG, Sawada T, Castleberry RP, et al. Do children benefit from mass screening for neuroblastoma?. Lancet. 1991;337:344–346
  14. Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc JM, Brisson LC, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet. 1996;348:1682–1687
  15. Bessho F, Hashizume K, Nakajo T, Kamoshita S. Mass screening in Japan increased the detection of infants with neuroblastoma without a decrease in cases in older children. J Pediatr. 1991;119:237–241
  16. Schilling FH, Spix C, Berthold F, Erttmann R, Sander J, Treuner J, et al. Children may not benefit from neuroblastoma screening at 1 year of age (Updated results of the population based controlled trial in Germany). Cancer Lett. 2003;197:19–28
  17. Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med. 2004;350:2010–2011
  18. Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N, et al. Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med. 1997;38:1352–1357
  19. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247
  20. Katzenstein HM, Cohn SL, Shore RM, Bardo DM, Haut PR, Olszewski M, et al. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol. 2004;22:3909–3915
  21. Mc Dowell H, Losty P, Barnes N, Kokai G. Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2009;52:552
  22. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, et al. International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874–1881
  23. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–1477
  24. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. INRG Task Force The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298–303
  25. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27:289–297
  26. London WB, Boni L, Simon T, Berthold F, Twist C, Schmidt ML, et al. The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett. 2005;228:257–266
  27. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005;23:6459–6465
  28. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005;23:6474–6480
  29. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Study. J Clin Oncol. 2005;23:6466–6473
  30. Schüz J, Kaletsch U, Meinert R, Kaatsch P, Spix C, Michaelis J. Risk factors for neuroblastoma at different stages of disease (Results from a population-based case-control study in Germany). J Clin Epidemiol. 2001;54:702–709
  31. Evans AE. Staging and treatment of neuroblastoma. Cancer. 1980;45(suppl 7):1799–1802
  32. Hayes FA, Green A, Hustu HO, Kumar M. Surgicopathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases. J Pediatr. 1983;102:59–62
  33. Shuster JJ, McWilliams NB, Castleberry R, Nitschke R, Smith El, Altshuler G, et al. Serum lactate dehydrogenase in childhood neuroblastoma (A Pediatric Oncology Group recursive partitioning study). Am J Clin Oncol. 1992;15:295–303
  34. Berthold F, Engelhardt-Fahrner U, Schneider A, Schumacher R, Zieschang J. Age dependence and prognostic impact of neuron specific enolase (NSE) in children with neuroblastoma. In Vivo. 1991;5:245–247
  35. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999;17:2264–2279
  36. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, et al. Correlation between morphologic and other prognostic markers of neuroblastoma (A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group). Cancer. 1993;71:3173–3181
  37. Shimada H, Chatten J, Newton WA, Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73:405–416
  38. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86:364–372
  39. Sano H, Bonadio J, Gerbing RB, London WB, Matthay KK, Lukens JN, et al. International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. Eur J Cancer. 2006;42:1113–1119
  40. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313:1111–1116
  41. Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et al. International Neuroblastoma Risk Group Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2009;27:365–370
  42. Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, et al. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? (A Children's Oncology Group study). Clin Cancer Res. 2006;12:5693–5697
  43. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) biology committee. Br J Cancer. 2009;100:1471–1482
  44. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9:581–591
  45. Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith El, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group Study. J Natl Cancer Inst. 1997;89:373–380
  46. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005;23:6466–6473
  47. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol. 2008;26:913–918
  48. Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005;23:8819–8827
  49. Attiyeh EF, London WB, Mossé YP, Wang Q, Winter C, Khazi D, et al. Children's Oncology Group Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–2253
  50. Ryden M, Sehgal R, Dominici C, Schilling FH, Ibáñez CF, Kogner P. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer. 1996;74:773–779
  51. Kramer K, Cheung NK, Gerald WL, LaQuaglia M, Kushner BH, LeClerc JM, et al. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. Eur J Cancer. 1997;33:2098–2100
  52. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002;62:6462–6466
  53. Ohira M, Oba S, Nakamura Y, Hirata T, Ishii S, Nakagawara A. A review of DNA microarray analysis of human neuroblastomas. Cancer Lett. 2005;228:5–11
  54. Cheung IY, Feng Y, Vickers A, Gerald W, Cheung NK. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn. 2007;9:237–241
  55. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–935
  56. Tanaka T, Slamon DJ, Shimoda H, Waki C, Kawaguchi Y, Tanaka Y, et al. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res. 1988;48:1030–1034
  57. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther. 2005;4:547–553
  58. Maris JM, Mosse YP, Bradfield JP, Hou C, Monni S, Scott RH, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med. 2008;358:2585–2593
  59. Alvarado CS, London W, Look AT, Brodeur GM, Altmiller DH, Thorner PS, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2000;22:197–205
  60. Ikeda H, Suzuki N, Takahashi A, Kuroiwa M, Nagashima K, Tsuchida Y, et al. Surgical treatment of neuroblastomas in infants under 12 months of age. J Pediatr Surg. 1998;33:1246–1250
  61. Perez CA, Matthay KK, Atkinson JB, Seeger RC, Shimada H, Haase GM, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group Study. J Clin Oncol. 2000;18:18–26
  62. Kushner BH, Cheung NK, LaQuaglia MP, Ambros PF, Ambros IM, Bonilla MA, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol. 1996;14:373–381
  63. Nitschke R, Smith EI, Altshuler G, Altmiller D, Shuster J, Green A, et al. Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study. Pediatr Blood Cancer. 2009;52:552
  64. Alvarado CS, Kretschmar C, Toledano S, Cantor A, Strother D, et al. Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study. J Pediatr Hematol Oncol. 1997;19:62–67
  65. Okuyama C, Ushijima Y, Kubota T, Nakamura T, Kikkawa M, Nishimura T. Utility of follow-up studies using meta-(123I)iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl Med Commun. 2002;23:663–672
  66. Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer. 2003;39:1899–1903
  67. Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol. 2005;23:8483–8489
  68. Boutros J, Bond M, Beaudry P, Blair GK, Skarsgard ED. Case selection in minimally invasive surgical treatment of neuroblastoma. Pediatr Surg Int. 2008;24:1177–1180
  69. Petty JK, Bensard DD, Partrick DA, Hendrickson RJ, Albano EA, Karrer FM. Resection of neurogenic tumors in children: is thoracoscopy superior to thoracotomy?. J Am Coll Surg. 2006;203:699–703
  70. McGregor LM, Rao BN, Davidoff AM, Billups CA, Hongeng S, Santana VM, et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude children's research hospital experience. Cancer. 2005;104:2837–2846
  71. Strother D, van Hoff J, Rao PV, Smith El, Shamberger RC, Halperin EC, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer. 1997;33:2121–2125
  72. Castleberry RP, Shuster JJ, Altshuler G, Smith El, Nitschke R, Winick N, et al. Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: a Pediatric Oncology Group study. J Clin Oncol. 1992;10:1299–1304
  73. Evans AE, Silber JH, Shpilsky A, D'Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol. 1996;14:2504–2510
  74. Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, et al. Societe Française d'Oncologie Pediatrique N-myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. J Clin Oncol. 1997;15:1171–1182
  75. Kushner BH, Kramer K, LaQuaglia MP, Cheung NK. Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy. J Pediatr Hematol Oncol. 2003;25:515–519
  76. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998;16:1256–1264
  77. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol. 2000;18:477–486
  78. De Bernardi B, Balwierz W, Bejent J, Cohn SL, Garrè ML, Iehara T, et al. Epidural compression in neuroblastoma: diagnostic and therapeutic aspects. Cancer Lett. 2005;228:283–299
  79. Boztug K, Kiely E, Roebuck DJ, Gaze M, Begent J, Brock P, et al. Successful treatment of MYCN amplified, progressive stage 4S neuroblastoma in a neonate with hepatic artery embolization in addition to multimodality treatment. Pediatr Blood Cancer. 2006;46:253–257
  80. Schleiermacher G, Rubie H, Hartmann O, Bergeron C, Chastagner P, Mechinaud F, et al. Neuroblastoma Study Group of the French Society of Paediatric Oncology Treatment of stage 4s neuroblastoma—report of 10 years' experience of the French Society of Paediatric Oncology (SFOP). Br J Cancer. 2003;89:470–476
  81. Hoover M, Bowman LC, Crawford SE, Stack C, Donaldson JS, Grayhack JJ, et al. Long-term outcome of patients with intraspinal neuroblastoma. Med Pediatr Oncol. 1999;32:353–359
  82. Rubie H, Hartmann O, Giron A, Lemoine G, Gruner M, Brugieres L, et al. Nonmetastatic thoracic neuroblastomas: a review of 40 cases. Med Pediatr Oncol. 1991;19:253–257
  83. Plantaz D, Rubie H, Michon J, Mechinaud F, Coze C, Chastagner P, et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease (A prospective study of 42 patients—results of the NBL 90 study of the French Society of Pediatric Oncology). Cancer. 1996;78:311–319
  84. Katzenstein HM, Kent PM, London WB, Cohn SL. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol. 2001;19:1047–1055
  85. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9:581–591
  86. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children's Cancer Group study. J Clin Oncol. 2000;18:1260–1268
  87. Grahm-Pole JG, Casper J, Elfenbein G, Gee A, Gross S, Janssen W, et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9:1094
  88. Matthay KK, O'Leary MC, Ramsay NK, Villablanca J, Reynolds CP, Atkinson JB, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer. 1995;31A:572–575
  89. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Children's Cancer Group Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. N Engl J Med. 1999;341:1165–1173
  90. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348–357
  91. Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000;18:2567–2575
  92. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002;20:2284–2292
  93. Pole JG, Casper J, Elfenbein G, Gee A, Gross S, Janssen W, et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9:152–158
  94. Stram DO, Matthay KK, O'Leary M, Reynolds CP, Haase GM, Atkinson JB, et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J Clin Oncol. 1996;14:2417–2426
  95. Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, et al. Children's Oncology Group Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51:747–753
  96. Garaventa A, Rondelli R, Lanino E, Dallorso S, Dini G, Bonetti F, et al. Myeloablative therapy and bone marrow rescue in advanced neuroblastoma (A report from the Italian Bone Marrow Transplant Registry. Italian Association of Pediatric Hematology-Oncology, BMT Group). Bone Marrow Transplant. 1996;18:125–130
  97. Flandin I, Hartmann O, Michon J, Pinkerton R, Coze C, Stephan JL, et al. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma (A study of the French Society of Pediatric Oncology). Int J Radiat Oncol Biol Phys. 2006;64:1424–1431
  98. Ladenstein R, Lasset C, Hartmann O, Klingebiel T, Bouffet E, Gadner H, et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1994;14:37–46
  99. Adkins ES, Sawin R, Gerbing RB, London WB, Matthay KK, Haase GM. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group Study. J Pediatr Surg. 2004;39:931–936
  100. La Quaglia MP, Kushner BH, Su W, Heller G, Kramer K, Abramson S, et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg. 2004;39:412–417
  101. von Allmen D, Grupp S, Diller L, Marcus K, Ecklund K, Meyer J, et al. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J Pediatr Surg. 2005;40:936–941
  102. Castleberry RP, Kun LE, Shuster JJ, Altshuler G, Smith IE, Nitschke R, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. J Clin Oncol. 1991;9:789–795
  103. Haas-Kogan DA, Swift PS, Selch M, Haase GM, Seeger RC, Gerbing RB, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003;56:28–39
  104. Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer. 2004;100:1268–1275
  105. Paulino AC, Fowler BZ. Risk factors for scoliosis in children with neuroblastoma. Int J Radiat Oncol Biol Phys. 2005;61:865–869
  106. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2000;18:4067–4076
  107. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid (Children's Cancer Group). N Engl J Med. 1999;341:1165–1173
  108. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group Study. J Clin Oncol. 2009;27:1007–1013
  109. Yu AL, Gilman AL, Ozkaynak MF, London S, Kreissman HX, Chen KK, et al. 2009 ASCO Annual Meeting A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032 [abstract 10067z]. J Clin Oncol. 2009;27(suppl):15s
  110. Wu ZL, Schwartz E, Seeger R, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 1986;46:440–443
  111. Cheung N-KV, Yu AL. Immunotherapy of neuroblastoma. In:  Brodeur GM,  Sawada T,  Tsuchida Y,  Voute PA editor. Neuroblastoma. Amsterdam, The Netherlands: Elsevier Science; 2000;p. 541–560
  112. Cheung NK, Kushner BH, Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am. 2001;15:853–866
  113. Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother. 1992;35:199–204
  114. Yu AL, Uttenreuther-Fischer MM, Huang CS. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169–2180
  115. Murray JL, Cunningham JE, Brewer H, Mujoo K, Zukiwski AA, Podoloff DA, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol. 1994;12:184–193
  116. Yu AL, Uttenreuther MM, Kamps A, Batova A, Reisfeld RA. Combined use of a human-mouse chimeric anti-GD2 (ch14.18) and GM-CSF in the treatment of refractory neuroblastoma. Antibody Immunoconjugates Radiopharmaceuticals. 1995;8:12
  117. Kushner BH, Kramer K, LaQuaglia MP, Cheung NK. Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy. J Pediatr Hematol Oncol. 2003;25:515–519
  118. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer Immunol Immunother. 1997;80:317–333
  119. Gilman AL, Ozkaynak MF, Matthay KK, Krailo M, Yu AL, Gan J, et al. Phase I study of ch14.18 with GM-CSF and IL-2 in children with neuroblastoma following autologous bone marrow transplant or stem cell rescue (A report from the Children's Oncology Group). J Clin Oncol. 2009;27:85–91
  120. Saylors RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. The Pediatric Oncology Group Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463–3469
  121. Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a Pediatric Oncology Group study. J Clin Oncol. 2004;22:4119–4126
  122. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am. 2001;15:867–910
  123. Lovat PE, Ranalli M, Annichiarrico-Petruzzelli M, Bernassola F, Piacentini M, Malcolm AJ, et al. Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp Cell Res. 2000;260:50–60
  124. Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, et al. Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer. 2001;94:314–321
  125. Munn DH, Cheung NK. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res. 1987;47:6600–6605
  126. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer. 1997;80:317–333
  127. Pardo N, Marti F, Fraga G, Illa J, Badell I, Peiró M, et al. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med Pediatr Oncol. 1996;27:534–539
  128. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA. 1996;93:7826–7831
  129. Troncone L, Riccardi R, Montemaggi P, Rufini V, Lasorella A, Mastrangelo R. Treatment of neuroblastoma with 131I-metaiodobenzylguanidine. Med Pediatr Oncol. 1987;15:220–223
  130. Hartmann O, Lumbroso J, Lemerle J, Schlumberger M, Ricard M, Aubert B, et al. Therapeutic use of 131I-metaiodobenzylguanidine (MIBG) in neuroblastoma: a phase II study in nine patients. Med Pediatr Oncol. 1987;15:205–211
  131. Treuner J, Gerein V, Klingebiel T, Schwabe D, Feine U, Happ J, et al. MIBG-treatment in neuroblastoma: experiences of the Tübingen/Frankfurt group. Prog Clin Biol Res. 1988;271:669–678
  132. Lewis IJ, Lashford LS, Fielding S, Flower MA, Meller S, Kemshead JT, et al. A phase I/II study of 131I mIBG in chemo-resistant neuroblastoma (The United Kingdom Children's Cancer Study Group (UKCCSG)). Prog Clin Biol Res. 1991;366:463–469
  133. Klingebiel T, Berthold F, Treuner J, Schwabe D, Fischer M, Feine U, et al. Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Pediatr Oncol. 1991;19:84–88
  134. Yanik GA, Levine JE, Matthay KK, Sisson JC, Shulkin BL, Shapiro B, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142

PII: S0147-0272(09)00069-5

doi: 10.1016/j.currproblcancer.2009.12.001

Current Problems in Cancer
Volume 33, Issue 6 , Pages 333-360 , November 2009

Article Tools

* Image Usage & Resolution